Therapy Areas: Allergy
Bryn Pharma Touts Effectiveness of UTULY 13.2mg Intranasal Epinephrine Spray
3 March 2023 - - US-based pharmaceutical company Bryn Pharma LLC has posted positive pharmacokinetic/pharmacodynamic (PK/PD) and safety data for its investigational 13.2mg intranasal epinephrine spray...
Arrowhead Releases Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
2 March 2023 - - US-based Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has posted interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company's investig...
Teva Presents New Data from CONNECT2 Study on its Digihaler System
28 February 2023 - - Israel-based Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) (TASE: TEVA) Teva Pharmaceuticals USA, Inc US affiliate has presented new data on its Digihaler System at ...
Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema
28 February 2023 - - US-based biopharmaceutical company Astria Therapeutics, Inc. (NASDAQ: ATXS) presented new STAR-0215 data in two poster presentations at the American Academy of Allergy, Asthm...
Aluna Raises USD 15.3m in Series B Funding
6 February 2023 - - US-based lung health management platform Aluna has completed a USD 15.3m series B round of financing to continue growing its solution among doctors and patients managing asthma, cy...
ALK's regulatory filing for house dust mite allergy tablet accepted for review in China
3 February 2023 - Danish pharmaceutical company ALK-Abelló A/S (ALK) (CPH:ALK-B) reported on Friday that its Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy...
Related Headlines

Loreaux, Humphries Named to Bryn Pharma Board of Directors

AcuCort signs exclusive commercial agreement with Kamada

MediPrint Ophthalmics Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Asset

Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma

DC4U and LUMC consortium receives grant to jointly develop Type I diabetes treatment

US FDA Accepts ARS Pharmaceuticals' NDA for neffy for the Treatment of Allergic Reactions (type I) including Anaphylaxis

Intravacc receives contract from US National Institute of Allergy and Infectious Diseases

First Volunteers Vaccinatated at Liberia Site in Phase I Clinical Trial of Lassa Fever Vaccine Candidate

First Volunteers Vaccinatated at Liberia Site in Phase I Clinical Trial of Lassa Fever Vaccine Candidate

First Volunteers Vaccinatated at Liberia Site in Phase I Clinical Trial of Lassa Fever Vaccine Candidate

First Volunteers Vaccinatated at Liberia Site in Phase I Clinical Trial of Lassa Fever Vaccine Candidate

First Volunteers Vaccinatated at Liberia Site in Phase I Clinical Trial of Lassa Fever Vaccine Candidate

First Volunteers Vaccinatated at Liberia Site in Phase I Clinical Trial of Lassa Fever Vaccine Candidate

First Volunteers Vaccinatated at Liberia Site in Phase I Clinical Trial of Lassa Fever Vaccine Candidate

First Volunteers Vaccinatated at Liberia Site in Phase I Clinical Trial of Lassa Fever Vaccine Candidate